Artivion Q4 revenue record $79.4M (+16.9%), net loss widens to $20.1M; guides 2022 rev $319-325M

ARTIVION, INC.

2021-FY EPS reported -$0.38 revenue$298,836,000

Q4 revenue $79.4M, up 16.9% GAAP; net loss ($20.1M) vs ($3.5M) in prior year.
Non-GAAP Q4 net loss ($141K) vs income $7.9M; full year non-GAAP net income $4.9M.
Full year revenue $298.8M (+18%); net loss ($14.8M) narrowed from ($16.7M) in 2020.
2022 outlook: constant currency revenue growth 9-11%; GAAP revenue $319-325M with $6M FX headwind.
FDA approved AMDS trial start; PMA filed for PerClot US approval; PROACT trials progressing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.